NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 309,674 shares, an increase of 384.3% from the November 30th total of 63,942 shares. Based on an average daily volume of 831,701 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the stock are sold short. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 831,701 shares, the short-interest ratio is presently 0.4 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NBY. C2C Wealth Management LLC lifted its position in NovaBay Pharmaceuticals by 78.2% during the 2nd quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 43,000 shares during the period. Apollon Wealth Management LLC acquired a new position in NovaBay Pharmaceuticals in the third quarter valued at approximately $35,000. Finally, Ground Swell Capital LLC acquired a new position in NovaBay Pharmaceuticals in the third quarter valued at approximately $25,000. 23.25% of the stock is owned by institutional investors and hedge funds.

NovaBay Pharmaceuticals Price Performance

Shares of NovaBay Pharmaceuticals stock traded up $0.10 during midday trading on Friday, hitting $4.85. 243,471 shares of the company were exchanged, compared to its average volume of 2,092,643. The firm has a market cap of $611.15 million, a P/E ratio of -0.49 and a beta of 0.57. NovaBay Pharmaceuticals has a 52 week low of $0.46 and a 52 week high of $6.47. The firm has a 50 day simple moving average of $1.76 and a 200-day simple moving average of $1.37.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.